Asklepios Biopharmaceutical operates as a AAV gene therapy company. The Company offers end-to-end gene therapy platform includes scaled-up manufacturing with its Pro10 cell line, AAV capsid library, and clinical programs for a range of genetic disease indications. Asklepios Biopharmaceutical serves customers in the State of North Carolina.